secwatch.observer — SEC 8-K summary
======================================

Issuer:     GALECTIN THERAPEUTICS INC (GALT)
CIK:        0001133416
Form:       8-K
Filed at:   2025-07-09T23:59:59+00:00
Accession:  0001140361-25-025295
Event type: debt
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galectin Therapeutics secures $10M line of credit from Chairman Uihlein; extends existing debt to Sept 2026
--------------------------------------------------------------------------------

- Richard E. Uihlein provides up to $10M unsecured line of credit; draws through April 2026, principal & interest due Sept 30, 2026.
- Interest at Applicable Federal Rate (currently 4.05%) plus 2%; conversion price floor $3.00 per share.
- Up to 200,000 warrants issued ratably; exercise price 150% of closing price, capped at $10, floor $3.
- Company extends existing $81M in convertible notes & lines of credit to September 30, 2026.
- Board approves $100K retention bonuses for CMO Dr. Khurram Jamil & CFO Jack Callicutt; partnership bonus if belapectin deal by Dec 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133416/000114036125025295/0001140361-25-025295-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133416/000114036125025295/ef20051584_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-025295

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer